Marco Banini

MD, Radiation Oncologist in Azienda Ospedaliero Universitaria Careggi, Florence

[Marco Banini @MarcBa12]

The path is set! Keep following up and don’t miss your opportunity to join the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments.
REGISTER HERE 👉 https://t.co/17PAzkKVv4

[CarlottaB @CarlottaB]

🗺️ Follow the roadmap to consensus on the integration of radiation therapy with new systemic treatments in head & neck cancer https://t.co/Scm85erlp1
📍 Looking forward to the Consensus in Florence, 9–10 October 2026
🤝 Let’s continue the discussion!
#oncoAlert #Oncology

[Pietro Garlatti @PietroGarlatti]

Great News in multimodality treatment in EGFRm IV stage Lung Cancer!

Northstar trial!
Sbrt ⬆️ PFS

https://t.co/dg3kmdZKUh
#ESMO25

[Pablo Jiménez @PaulJiL]

Nasopharyngeal Carcinoma #ESMO25

Superb review as always by Dr Bridgette Ma @CUHKofficial, with the touch from @DrMLChua and their teams

🔸Integration of EBV DNA in practice
🔸Possible de-escalation manoeuvres
🔸Challenging to navigate current evidence amid reimbursement restrictions

@myESMO @OncoAlert @brunolarvol

[Benjamin Besse @BenjaminBesseMD]

Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver.
@mihaela_aldea shows incidence, highest in ALK/RET/EGFR/ROS1.
AMG193 paved the way at #ESMO24.
BMS-986504 confirms druggability: 29% ORR + many durable SD (slide @CharuAggarwalMD). #WCLC25

[Benjamin Besse @BenjaminBesseMD]

ALEX final OS:
- crizo arm dragged down by <50% getting next-gen ALK. Lack of crossover really hurts.
- 5-yr OS with alectinib ≈ 5-yr PFS with lorlatinib (CROWN), but only 18% got lorla post alect — we still don’t know the optimal sequence. #ESMO25

[Pablo Jiménez @PaulJiL]

Amivantamab in Head&Neck SCC #ESMO25

Origami4 Cohort 1
86 R/M HNSCC patients after IO&platinum
🔹ORR 45% CBR 76%
🔹Time to first response 6 weeks
@myESMO @OncoAlert @brunolarvol

[Benjamin Besse @BenjaminBesseMD]

Morning > Afternoon for IO?
Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat).
Given IO’s long half-life, maybe only the timing of the first dose matters.
#ASCO2025

[Giulio Francolini @GiulioFrancoli1]

Wonderful to see in person the impact on clinical outcomes given by SBRT added on top of standard of care management across all subgroups of oligometastatic prostate cancer!,@ChadTangMD ,#GU25

[d.planchard @dplanchard]

A very pleasant moment of scientific exchange on lung cancer and conviviality with @HosseinBorghaei @GustaveRoussy A big thank you and honor for his presence at the Institute with our lung team ! @barlesi @BenjaminBesseMD @JordiRemon

[Jordi Remon @JordiRemon]

2024: Fortunately is difficult to merge all ttx for NSCLC 🫁 in 1 slide. Hwv, still pending:
✏️avoid “me too” approvals if prices not ⬇️
✏️ consol TKI for all and for lifetime?
✏️⬆️genotyping access & drug access
✏️➕ academic trials of de-escalating
✏️periop vs neoadj@OncoAlert

[Matthias Guckenberger @Mat_Guc]

Remember the misleading press reports about "brutal" #radonc after PROSPECT ?

This is what modern radiotherapy can achieve for elderly breast cancer patients!
👉 "Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 mo"
👉 oncological data awaited

[Mauro Loi @isteddos]

Great overview by @VSalvestrini and Andrea Lastrucci on SBRT for lung ultracentral tumors

https://t.co/2vEaRTfKc2

[Icro Meattini @Icro_Meattini]

Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #BreastCancer (EUROPA)
@TheLancetOncol

▶️ Share Link – 50 days' free access to the article (Jan 31, 2025):
https://t.co/jedNdGzeE7

[The Lancet Oncology @TheLancetOncol]

Presented at #SABCS24:

Interim results from the EUROPA trial:

Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer
https://t.co/ay6evWBQBG

[Marta Perachino @MartaPerachino]

Congrats @Icro_Meattini for your brilliant presentation and concomitant publication! @TheLancetOncol 🔥well deserved!!

[Icro Meattini @Icro_Meattini]

The Full Program for #SABCS24 is out @SABCSSanAntonio

Look who’s around…

#radonc #medonc #surgonc #BreastCancer #OncoAlert @OncoAlert @UNI_FIRENZE @AOUCareggi

https://t.co/vOot7OyCDw

[Jordi Remon @JordiRemon]

NEOSTAR trial: Similar to metastatic disease it seems that dual induction IO (antiCTLA4 + antiPD1) as induction treatment may benefit KRAS/STK11 versus nivo. New options for these tumors and prospective exploring dual IO in PDL1 Is challenging #ESMO24

[Jordi Remon @JordiRemon]

Thymic Epithelial Tumors remain a rare and orphan disease. Results of PECATI trial may help to ⬆️ patient outcomes with metastatic B3Thymoma and Thymic Carcinoma. Multidisciplinary approach is also crucial for these rare tumours #ESMO24

[Benjamin Besse @BenjaminBesseMD]

Adjuvant Durvalumab after resection of stage IB~IIIA NSCLC does not improve DFS. No predictive effect of PD-L1 expression as in KN-091/PEARLS (adj pembro): Biology of micrometastatic disease differs from matched primary tumor? Confirms that neoadjuvant is the way to go. #ESMO24

[Benjamin Besse @BenjaminBesseMD]

LIFETIME osimertinib after a treatment with curative intent?
In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts.
Were pts in LAURA properly staged by petscan/brain RMI?
Why not using MRD to select patient?
Strong concerns when OS is not positive. #ASCO24